NEW YORK (GenomeWeb) – BGI, Imperial College of London, and Waters today signed a framework agreement to accelerate translational medicine.
Through R&D projects incorporating omics-related and clinical applications, the partners plan to develop comprehensive standards and approaches for human omics testing and data analysis, BGI said. Work will focus on biomarker detection, as well as the integration of multidimensional data and information from 3D imaging, for example, in order to translate, accumulate, and update omics, clinical, and health knowledge.
BGI brings its expertise in genomics and informatics to the collaboration, while
Waters provides knowledge in LC-MS technology, biomarker data collection and visualization, and data management. Imperial College is a leader in metabolic phenotyping, imaging, and data analysis, BGI said.
Vince Gao, CEO of BGI Health, the clinical arm of BGI, said in a statement that through the collaboration, the partners expect to apply research to the prediction and prevention of diseases such as cancer and cardiovascular disease.